From 8K: "The Amendment effectuates a transfer of regulatory responsibilities, including the OMONTYS New Drug Application, or NDA, and ALL MANUFACTURING, and development responsibilities from the Company to Takeda."
Looks like $33M FUTURE contract manufacturing contract obligation is the responsibility of Takeda as well. If this is true, AFFY should reverse up in a big way.
Trying to contact the company to find out. Stay tuned!
That's a good question, they gave the drug away and cant stay on the market as a royalty collector with no staff. Question is if a buyout is going to happen why file the 8k for royalties that would void on a buyout.